Vera Therapeutics

Our Company

Our mission is to change the standard of care for patients with immunologic and rare diseases. We are developing multiple novel biologic molecules toward this end.

Our lead late-stage clinical candidate is atacicept:

  • Fully humanized TACI-Fc fusion protein that inhibits the two cytokines, BAFF and APRIL, that cause B cells and plasma cells to produce disease-causing antibodies
  • Potential best- and first-in-class dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure despite optimized supportive care
  • Demonstrated sustained eGFR stabilization through 72 weeks in the ORIGIN Phase 2b clinical trial for IgAN
  • ORIGIN 3, a pivotal Phase 3 clinical trial, initiated June 2023
  • Target profile: at-home self-administration by subcutaneous once weekly autoinjector

We also hold worldwide global rights to MAU868:

  • A monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells
  • Phase 2 clinical trial showed MAU868 was well tolerated and showed clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia
  • No BK-specific treatment currently available
  • Target profile: monthly IV administration

Our Leadership Team

Executive Team
Marshall Fordyce, MD's Photo

Marshall Fordyce, MD

CEO and Founder

Robert M. Brenner, MD's Photo

Robert M. Brenner, MD

Chief Medical Officer

Lauren Frenz, MBA's Photo

Lauren Frenz, MBA

Chief Business Officer

Sean Grant, MBA's Photo

Sean Grant, MBA

Chief Financial Officer

David Johnson, MBA's Photo

David Johnson, MBA

Chief Operating Officer

William D. Turner's Photo

William D. Turner

Chief Development Officer

Kelly Rauber's Photo

Kelly Rauber

SVP, Human Resources

Senior Leadership
Joseph Young, MBA's Photo

Joseph Young, MBA

Chief Accounting Officer

Amit Sharma, MD, FASN, FACP, FNKF's Photo

Amit Sharma, MD, FASN, FACP, FNKF

EVP, Medical Affairs & Clinical Research

Gary Barrera, MBA's Photo

Gary Barrera, MBA

SVP, Regulatory Affairs & Quality Assurance

Julien E. Capers, JD's Photo

Julien E. Capers, JD

SVP, Legal

Kerry Cooper, MD's Photo

Kerry Cooper, MD

SVP, Medical Affairs

Tom Doan's Photo

Tom Doan

SVP, Development Operations

Neeraj Pakala, PhD, MBA's Photo

Neeraj Pakala, PhD, MBA

SVP, Product Development and Manufacturing

Lijie Zhong, PhD, MBA's Photo

Lijie Zhong, PhD, MBA

SVP, Biometrics

Alvin Lin, MBA's Photo

Alvin Lin, MBA

VP, Commercial Strategy

Dmitriy Ter-Martirosov, MBA's Photo

Dmitriy Ter-Martirosov, MBA

VP, Product & Portfolio Management

Amy Wang's Photo

Amy Wang

VP, Business Development & Alliance Management

Board of Directors

Michael M. Morrissey, PhD's Photo

Michael M. Morrissey, PhD

President and CEO
Exelixis

Andrew Cheng, MD, PhD's Photo

Andrew Cheng, MD, PhD

President and CEO

Akero Therapeutics
Beth Seidenberg, MD's Photo

Beth Seidenberg, MD

General Partner

Kleiner Perkins
Maha Katabi, PhD, CFA's Photo

Maha Katabi, PhD, CFA

General Partner

Sofinnova Investments
Patrick Enright, MBA's Photo

Patrick Enright, MBA

Managing Director

Longitude Capital
Scott Morrison's Photo

Scott Morrison

Former Partner and US Life Sciences Leader

EY
Marshall Fordyce, MD's Photo

Marshall Fordyce, MD

President and CEO

Vera Therapeutics
Kimball Hall's Photo

Kimball Hall

President and CEO

Innocoll Biotherapeutics
Christy J. Oliger's Photo

Christy J. Oliger

Former SVP Commercial

Genentech
Top